TICAM2抗体

TICAM2 (TIR domain-containing adaptor molecule 2), also known as TRAM, is a key adaptor protein in the Toll-like receptor (TLR) signaling pathway, primarily involved in mediating immune responses to pathogens. It facilitates signal transduction from TLR4 and TLR3. activating downstream transcription factors like NF-κB and interferon regulatory factors (IRFs) to induce pro-inflammatory cytokines and type I interferons. TICAM2 antibodies are essential tools for studying its expression, localization, and functional mechanisms in innate immunity. These antibodies enable researchers to detect TICAM2 via techniques such as Western blotting, immunofluorescence, and immunoprecipitation, aiding in the exploration of its role in TLR4-mediated responses to lipopolysaccharides (LPS) and viral nucleic acids. Structurally, TICAM2 contains a TIR domain critical for interactions with other signaling molecules, including TICAM1 (TRIF), forming a bridge between receptor activation and downstream pathways. Studies using TICAM2 antibodies have revealed its importance in early-phase TLR4 signaling and its crosstalk with MyD88-independent pathways. Dysregulation of TICAM2 is linked to chronic inflammation, autoimmune diseases, and cancer, making it a potential therapeutic target. Antibodies against TICAM2 thus support both basic research and drug development, offering insights into immune regulation and pathogenic mechanisms.